20 - 30 % of patients with acute myeloid leukemia have mutations of the FLT3 biomarker that make them eligible for several FLT3 - targeted small
molecule therapies currently in late stage clinical trials.
Not exact matches
Basic research on cancer mechanisms has led to over 40 targeted cancer
therapies currently on the market, which take the form of monoclonal antibodies, small
molecule drugs, and immunotherapies.
«As a bridging
therapy between the really good outcomes we have
currently and maybe a cure down the line,» says Pipe, «I think the extended - half - life
molecules are a perfect transition.»
We are
currently developing small
molecule Nav1.1 activators that increase Nav1.1 currents and interneuron - dependent gamma oscillations in vitro and in vivo to develop novel
therapies for conditions with impaired interneuron function, including AD and Dravet syndrome.
The company's lead candidate, GLN - 1001, is a first - in - class, orally available oncolytic small
molecule,
currently being developed as a potentially disease modifying
therapy for glioblastoma by targeting specific vulnerabilities in tumor cells.